An interventional study of Inosine pranobex in HIV Infections, sponsored by Newport Pharmaceuticals International. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.
Sponsored by Newport Pharmaceuticals International · Not applicable, Interventional, and Treatment
Among 2,802 studies in HIV Infections with a site in United States — 83 open to participants now, 140 under way, 11 of them phase 3. HIV Infections · United States.
Among the 2,802 studies in HIV Infections with a site in United States, this one is one of 718 with no phase, and was the 4th registered.
4,734 studies on the registry are indexed under HIV Infections; 244 are open to participants now.
Browse HIV Infections studies →83 of the 2,802 studies in HIV Infections with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+
ViiV Healthcare · Sites in United States
Ages 18–55 · Healthy volunteers
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 40+
American University · Sites in United States
Ages 18+ · Men only
Gilead Sciences · Sites in United States, Australia, Japan
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 158 HIV Infections studies recruiting now, 104 (66%) set no upper age limit and 41 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,802 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 749 · Phase 2 588 · Phase 3 337 · Phase 4 157
First in 1984; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 60 across the 2,150 interventional studies, 135 across the 350 observational. Of the 2,530 that completed or were terminated, 558 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
857 of 2,802 have an industry lead sponsor. The 10 most frequent:
Newport Pharmaceuticals International is the lead sponsor of 6 studies on the registry; none are open to participants now.
Newport Pharmaceuticals International has 6 studies filed under HIV Infections — fewer than ten, so there is no comparison to draw.
51 of the studies in HIV Infections with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06550804Phase 3University of Illinois at ChicagoTesting a Real-time Electronic Antiretroviral Adherence Monitoring Intervention | 2027-03 |
| NCT04833829Emory UniversityCross-disciplinary HIV Integrated Mental Health Support Intervention | 2026-11 |
| NCT04577313University of ConnecticutHIV Treatment Adherence Dose Determination Trial | 2026-11-30 |
| NCT06679751Boston Medical CenterInfectious Disease (ID) Testing OUtreach in Carceral Hubs | 2026-12 |
| NCT06868641Columbia UniversityThe TAIL-PrEP Study | 2026-12 |
Add all 51 to your calendar (.ics) → With an account.
Among the 2,802 studies in HIV Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to:
Exclusion Criteria
Co-existing Condition:
Patients with the following are excluded:
Concurrent Medication:
Excluded:
Concurrent Treatment:
Excluded:
The following are excluded:
Prior Medication:
Excluded:
Patients who fall into the group which is at risk of developing cutaneous sarcoma and/or opportunistic diseases but at present have no signs or symptoms of these diseases.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is completed, as verified in Jun 1989. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inosine Pranobex
Newport Pharmaceuticals International